articleThe LancetFeb 1, 2011Closed access

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

University of Santo Tomas Hospital · Hospital Británico de Buenos Aires · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,030
total citations
FWCI
99.83
Percentile
100%
References
42
Citations per year

Authors

17

Topics & keywords

Keywords
  • Belimumab
  • Medicine
  • B-cell activating factor
  • Internal medicine
  • Placebo
  • Clinical endpoint
  • Systemic lupus erythematosus
  • Lupus erythematosus
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding